- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06301945
Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors (INTHYM)
Artificial Intelligence for Histopathological Classification and Recurrence Prediction of Thymic Epithelial Tumors
Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection. Administration of postoperative radiotherapy is usually indicated in patients with more extensive local disease, incomplete resection and/or more aggressive subtypes, defined by the WHO histopathological classification.
In this classification thymoma types A, AB, B1, B2, B3, and thymic carcinoma are distinguished. Studies have shown large discordances between pathologists in subtyping these tumors. Moreover, the WHO classification alone does not accurately predict the risk of recurrence, as within subtypes patients have divergent prognoses.
The investigators will develop AI models using digital pathology and relevant clinical variables to improve the accuracy of histopathological classification of thymic epithelial tumors, and to better predict the risk of recurrence.
In this multicentric and international project three existing databases will be used from Rotterdam, Maastricht and Lyon. For all models one database will be used to build AI models, and the other two for external validation.
The ultimate goal of this project is to develop AI models that support the pathologist in correctly subtyping thymic epithelial tumors, in order to prevent patients from under- or overtreatment with adjuvant radiotherapy.
Study Overview
Status
Intervention / Treatment
Detailed Description
Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection. Administration of postoperative radiotherapy is usually indicated in patients with more extensive local disease, incomplete resection and/or more aggressive subtypes, defined by the WHO histopathological classification.
In this classification thymoma types A, AB, B1, B2, B3, and thymic carcinoma are distinguished. Studies have shown large discordances between pathologists in subtyping these tumors. Moreover, the WHO classification alone does not accurately predict the risk of recurrence, as within subtypes patients have divergent prognoses.
We will develop AI models using digital pathology and relevant clinical variables to improve the accuracy of histopathological classification of thymic epithelial tumors, and to better predict the risk of recurrence.
In this multicentric and international project three existing databases will be used from Rotterdam, Maastricht and Lyon. For all models one database will be used to build AI models, and the other two for external validation.
The ultimate goal of this project is to develop AI models that support the pathologist in correctly subtyping thymic epithelial tumors, in order to prevent patients from under- or overtreatment with adjuvant radiotherapy.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Anna Salut Esteve Domínguez
- Phone Number: 0107043491
- Email: a.estevedominguez@erasmusmc.nl
Study Locations
-
-
South Holland
-
Rotterdam, South Holland, Netherlands, 3015 GD
- Recruiting
- Erasmus MC
-
Contact:
- Anna Salut Esteve Domínguez
- Email: a.estevedominguez@erasmusmc.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Study Population:
This study focuses on individuals diagnosed with thymic epithelial tumors. The study includes patients from three datasets: Erasmus MC (710 patients), Maastro (137 patients), and University Hospital Lyon (181 patients).
Additional Information:
- Erasmus MC (710 patients): Includes age, gender, and diagnosis information; each patient may have multiple whole slide images.
- Maastro (137 patients): Each patient may have multiple whole slide images.
- University Hospital Lyon (181 patients): Each patient may have multiple whole slide images.
Description
Inclusion Criteria:
Participants with specific diagnoses are eligible for inclusion in the study. The eligible diagnoses include various subtypes of thymoma and thymic carcinoma, specifically:
- Thymoma A
- Thymoma AB
- Thymoma B1
- Thymoma B2
- Thymoma B3
- Thymic Carcinoma
Inclusion is based on a consensus diagnosis with a level of agreement less than 70%. This criterion is applied during the training phase of the model.
Recurrence Criteria:
Participants with a documented recurrence outcome within a 5-year period are considered eligible for this aspect of the study. This criterion is primarily applied during the validation phase.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with TET
Patients diagnosed with the following TET subtypes:
|
AI Diagnostics uses advanced algorithms for precise histological image analysis to help diagnose disease, including subtype.
Other Names:
|
Recurrence
Patients with thymic epithelial tumors who have experienced recurrence.
|
This AI tool evaluates thymic tumour data and other clinical data and calculates the risk of recurrence, with the aim of analysing whether there is an association with specific subtypes of thymic epithelial tumours and clinical data.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
WP1 - Databases/Data Pre-processing
Time Frame: M1-M18
|
The EMC-dataset includes 179 TET-patients classified by experienced TET-pathologists.
Cases with good agreement between pathologists will be used for training AI-models.
Evaluation includes digitized pathology slides assessed by an international expert-panel.
The MUMC-database (137 patients) and CHUL-database (181 patients) provide additional data, including clinical variables.
Relevant factors include age, gender, tumor volume, stage, completeness of resection, autoimmune disorders, and treatment details.
|
M1-M18
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
WP2 - Deep Learning-Model for TET Classification and Recurrence Prediction
Time Frame: M6-M32
|
This outcome aims to create an AI-framework with two principal goals.
First, investigate TET-subtypes using four different models emphasizing cell type, morphological structures, and a combination.
Second, classify patients based on recurrence outcome within 5 years.
An ablation study will be conducted with state-of-the-art deep learning classifiers (ResNet, Inception).
|
M6-M32
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
WP3: Clinical Evaluation
Time Frame: M6-M36
|
AI-models 1-3 will be built and validated on the EMC-database, while AI-model 4 will be built on the MUMC+-database and validated on both.
Model performance will be assessed using sensitivity, specificity, negative/positive predictive value.
Decision analysis curves will quantify the clinical benefit, identifying patient groups with the largest utility.
|
M6-M36
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Wolf JL, van Nederveen F, Blaauwgeers H, Marx A, Nicholson AG, Roden AC, Strobel P, Timens W, Weissferdt A, von der Thusen J, den Bakker MA. Interobserver variation in the classification of thymic lesions including biopsies and resection specimens in an international digital microscopy panel. Histopathology. 2020 Nov;77(5):734-741. doi: 10.1111/his.14167. Epub 2020 Sep 24.
- Molina TJ, Bluthgen MV, Chalabreysse L, de Montpreville VT, de Muret A, Dubois R, Hofman V, Lantuejoul S, le Naoures C, Mansuet-Lupo A, Parrens M, Piton N, Rouquette I, Secq V, Girard N, Marx A, Besse B. Impact of expert pathologic review of thymic epithelial tumours on diagnosis and management in a real-life setting: A RYTHMIC study. Eur J Cancer. 2021 Jan;143:158-167. doi: 10.1016/j.ejca.2020.11.011. Epub 2020 Dec 11.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Maastro Clinic
- 72725524 (Other Grant/Funding Number: Hanarth Fonds)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thymic Carcinoma
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingUnresectable Thymic Carcinoma | Metastatic Thymic Carcinoma | Locally Advanced Thymic Carcinoma | Recurrent Thymic CarcinomaUnited States
-
Fudan UniversityRecruitingThymoma and Thymic CarcinomaChina
-
National Cancer Institute (NCI)CompletedThymic Carcinoma | Thymoma | Thymic Carcinoid | Thymic Neuroendocrine TumorsUnited States
-
MedSIRMerck Sharp & Dohme LLCActive, not recruitingMetastatic Thymic Carcinoma | Thymoma Type B3Spain, France, Italy
-
Shanghai Chest HospitalRecruitingThymic Carcinoma | Thymic Epithelial Tumor | Thymic CancerChina
-
Shanghai Pulmonary Hospital, Shanghai, ChinaRecruiting
-
Fudan UniversityRecruiting
-
National Cancer Institute (NCI)TerminatedInvasive Thymoma and Thymic Carcinoma | Recurrent Thymoma and Thymic Carcinoma | Stage III Thymoma | Stage IVA Thymoma | Stage IVB ThymomaUnited States
-
Fudan UniversityCompletedThymoma and Thymic CarcinomaChina
-
Sun Yat-sen UniversityActive, not recruitingThymoma and Thymic CarcinomaChina
Clinical Trials on Artificial Intelligence Diagnostics
-
Docbot, Inc.RecruitingColorectal Adenoma | Colorectal Adenocarcinoma | Colorectal Polyp | Colorectal SSAUnited States
-
Istituto Clinico HumanitasRecruitingArtificial IntelligenceItaly
-
Istituto Clinico HumanitasCompletedArtificial IntelligenceItaly
-
Fondazione Policlinico Universitario Agostino Gemelli...Azienda Ospedaliero-Universitaria di Parma; Ministero della Salute, Italy; Ospedale...RecruitingBrain Malformation | Fetal AnomalyItaly
-
National Taiwan University HospitalRecruiting
-
Rajavithi HospitalHealth Systems Research Institute; Google LLC.RecruitingDiabetic Retinopathy | Artificial Intelligence | ScreeningThailand
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNot yet recruiting
-
Al Baraka Fertility HospitalAl-Azhar UniversityRecruitingARTIFICIAL INTELLIGENCE (AI) APPLICATIONS IN REPRODUCTIVE MEDICINEEgypt
-
West China HospitalRecruitingInfantile Hemangiomas | Neck Mass | Thyroglossal Duct Cysts | Branchial Cleft Anomalies | Dermoid and Epidermoid Cysts | TeratomasChina